Forbion

Page Down

Our Focus

At Forbion Capital Partners we invest in Life Sciences and Biomedical Technology companies developing world-class drugs and technologies, with a clear focus on product development.

 

The Forbion team is specialized in the evaluation of late stage preclinical / early stage clinical development programs. We focus on companies that have innovative technologies and drug development programs with unique advantages over current treatments. Furthermore, we invest in medical device companies with a special focus on interventional devices in cardiology, gastroenterology and pulmonology that are close to market approval.

 

Our involvement continues beyond the initial investment. We work closely with scientists, academic institutions, entrepreneurs and industry experts to accelerate the development and to optimize the commercial potential of our portfolio company's products and technologies.

 

The Forbion team began operating in 2000 as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December 2006 the group broadened its investor base, became independent, and changed its name to Forbion Capital Partners. Throughout this time the Forbion team made new investments and has successfully divested from a series of companies, including PneumRx, Santaris, Biovex, Pathway, Impella, Alantos, Glycart, Acorda, Argenta, Fovea and Borean.

 

Current funds under management exceed EUR 540M, split between five active funds and comprising some 28 promising portfolio companies. FCF III recently had its first close at EUR 92M, the aim is to raise EUR 150-200M.

 

Part of the capital invested from Forbion Capital Partner’s funds is provided by the ERP-EIF facility and the LfA-EIF facility, which is managed by the European Investment Fund, and from the KFW through the ERP - Venture Capital Fondsfinanzierung facility.

 

Forbion closely collaborates with BioGeneration Ventures, a Netherlands-based venture capital firm investing in Dutch start-up and early stage life sciences companies.

 

 

If you would like to receive regular news on LinkedIn and stay connected with us, please follow us on LinkedIn

 

 

"The Forbion team always follows a hands-on approach when working with companies and has impressed me with its professional competence and broad industry network."


Joel Jean-Mairet
Managing Partner, YSIOS Capital, Spain and previous CEO of Glycart AG, Switzerland
Page Up Page Down

Team

  • Investment Team

    Having invested and worked together since 2000, the Investment Team has a broad strategic network of relationships and has been active on a combined 49 boards of Forbion portfolio companies. The principals typically take a collaborative approach to reviewing transactions that leverage their combined clinical, financial, operational and management expertise.

    "We empower entrepreneurs to foster healthcare innovation."
  • Holger Reithinger, Ph.D.

    General Partner

    linkedin
    Phone+49 172 252 9032 PhoneHolger.Reithinger@forbion.com VCardDownload vCard
    "We partner with innovation-driven entrepreneurs to build successful businesses."
    more about me >
  • Philip Astley-Sparke FSA

    Venture Partner

    linkedin
    PhonePhilip.Astley-Sparke@forbion.com
    "True innovation is driven by a small minority who are able to create precedent rather than follow it."

    Managed portfolio companies

    more about me >
  • Cyril Lesser, MSc

    Controller

    Phone+31 35 699 3020 Phonecyril.lesser@forbion.com

    Cyril joined Forbion Capital Partners in October 2009 as Controller. His main focus lies in the financial and treasury operations as well as the accounting and tax reporting for all Forbion Capital partners’ entities.

    Prior to joining Forbion Capital Partners Cyril was a Senior Account Manager at a Trust office where he was responsible for a team dealing with the accounting, financial and tax aspects of several companies.

    Cyril holds a master’s degree in International Financial Economics from the University of Amsterdam and a master’s degree in fiscal law from the Free University of Amsterdam, The Netherlands.

  • Sander Slootweg MSc

    Managing Partner

    linkedin
    Phone+31 35 699 3015 Phonesander.slootweg@forbion.com VCardDownload vCard
    "Investing in the LS space can be very rewarding as financial success is often coupled to success for patients in new drugs and devices for high needs reaching the markets."
    more about me >
  • Bart Bergstein MSc

    Senior Advisor

    linkedin
    Phone+31 6 5243 3294 Phonebart.bergstein@forbion.com VCardDownload vCard
    "The beauty of this industry is that success is often both financial success and success for humanity."
    more about me >
  • Martien van Osch MSc

    Managing Partner

    linkedin
    Phone+31 35 699 3016 Phonemartien.van.osch@forbion.com VCardDownload vCard
    "Any ground-breaking idea needs the right recipe to become a commercial winner."
    more about me >
  • Marco Boorsma, Ph.D.

    Partner

    linkedin
    Phone+31 35 699 3022 PhoneMarco.Boorsma@forbion.com VCardDownload vCard
    "My favored ingredients to produce an extraordinary and successful innovative business? Optimal dosing of talent, entrepreneurship, and hard work."
    more about me >
  • John J.P. Kastelein, MD PhD FESC

    Advisor

    linkedin
    Phone+31 20 566 6612

    Prof. Kastelein advises Forbion on the cardiovascular and metabolic disease space and presents Forbion with investment opportunities in these fields.

     

    Dr. John Kastelein is professor of medicine, chairman of the department of vascular medicine, and holds the Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. Dr. Kastelein is a member of the Steering Committees of numerous lipid lowering and cardiovascular intervention trials. His main interest is in the development of novel therapies for Cardiovascular Diseases and the genetic basis of dyslipidemia. Dr. Kastelein was awarded a doctorate in Medicine (with Honours) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. He is president of the Dutch Atherosclerosis Society and the National Scientific Committee on Familial Hypercholesterolemia and also a Fellow of the European Society of Cardiology (FESC). In 2010 he was awarded the prestigious Dutch Heart Association prize of EUR 1 million and in 2011 the ZonMw Parel for his research in the field of gene therapy. 

     

  • Sander van Deventer MD Ph.D.

    Managing Partner

    linkedin
    Phone+31 6 54982592 Phonesander.van.deventer@forbion.com VCardDownload vCard
    "We bridge the chasm that separates research and development."
    more about me >
  • Rogier Rooswinkel, PhD

    Senior Analyst

    linkedin
    Phone+31 35 699 3000 Phonerogier.rooswinkel@forbion.com VCardDownload vCard
    "It always starts with good science, but only exits with good management."
    more about me >
  • Kapil Dhingra, PhD

    Advisor

    linkedin
    Phone+1 973 7293560 Phonekd1234@embarqmail.com

    Dr. Dhingra advises Forbion on opportunities in the oncology space. His vast network within the Pharma industry is a key asset to the Forbion portfolio companies that he is involved with.

     

    Dr. Kapil Dhingra is a medical oncologist and a physician-scientist. He is the founder of KAPital Consulting, LLC, a consulting company dedicated to assisting biotechnology, pharmaceutical and diagnostic companies realize the full promise of scientific, clinical and commercial advances in oncology. He received his medical training at the All India Institute of Medical Sciences, New Delhi, India, followed by an Internal Medicine Residency at Lincoln Medical Center, New York, NY and a Hematology-Oncology fellowship at Emory University, Atlanta, GA. In 1989, he joined the faculty of M.D. Anderson Cancer Center, Houston, Texas where he pursued laboratory and clinical cancer research, in addition to his direct patient care responsibilities. Dr. Dhingra joined Eli Lilly and Company in 1996 as Clinical Research Physician. He joined Roche in 1999 and was promoted, in 2002, to Vice President, Oncology. He played a key role in the dramatic expansion of Roche oncology enterprise leading to Roche becoming the global leader in oncology. In 2007, he was appointed Leader, Disease Biology Leadership Team, within Roche’s R&D model. Dr. Dhingra holds several Board positions including at  Forbion’s portfolio company Exosome Diagnostics. He previously served on the Board of BioVex and Micromet.

     

  • G-J Mulder, MD

    General Partner

    Phone+31 35 699 3018 Phonegeert-jan.mulder@forbion.com VCardDownload vCard
    "Art and Science have always driven innovation and translation of socially relevant ideas, both provide a framework for investing with high-value impact."
    more about me >
  • Avi Molcho MD MBA

    Venture Partner

    Phone+972 54 5555 957 PhoneAvi.Molcho@forbion.com VCardDownload vCard
    "The life of a startup is a rollercoaster. We have always been supportive of our companies through their ups and downs."

    Managed portfolio companies

    more about me >
  • Vincent van Houten, MSc

    VP Finance

    linkedin
    Phone+31 35 699 3019 Phonevincent.van.houten@forbion.com

    Vincent van Houten joined Forbion Capital Partners in 2007 and since then played an active role in setting up and maintaining the Forbion investment funds. Vincent holds a Masters degree from the University of Amsterdam and has a Finance and Accounting background. His focus includes the financial and fiscal activities of Forbion. Vincent is responsible for financial, reporting and fiscal topics of the various Forbion funds, as well as for the Forbion group related topics. Vincent has experience in corporate and fiscal (re)structuring. In that respect Vincent also assists the Investment Team on portfolio related financial topics. Prior to joining Forbion he worked at a trust office. 

  • Mathias Falcenberg, PhD

    Analyst

    linkedin
    Phone+49 89 416161951 Phonemathias.falcenberg@forbion.com VCardDownload vCard
    "Smart investments combine an exceptional management with ideas driven by innovation"
    more about me >
Page Up Page Down

News